Figure 3 | Scientific Reports

Figure 3

From: Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients

Figure 3

V565 distribution and co-localisation with CD3+ cells in colon biopsy sections from ulcerative colitis patients after receiving oral V565 over 7 days. Colon biopsies were taken before and after 7 days of V565 dosing (1665 mg/day) and were embedded in OCT, then snap-frozen. Biopsy sections were cut, fixed and incubated with anti V565 rabbit polyclonal antibody SY7915 and mouse anti-CD3, after which they were washed and incubated with anti rabbit IgG-Alexa 594, anti-mouse-Alexa 488 and Hoechst 33342. V565 associated fluorescence (red) was increased in sections from the post V565 treatment biopsies and some of it co-localised on (green) CD3+ cells (arrows and B). Nuclei are blue. Bar = 10 μm and 20 μm in A and B respectively.

Back to article page